Assessment of N-95 Facemask for Use in COVID-19 Pandemic in Case of Shortage of Personal Protective Equipment
A Proposed Alternative to the N-95 Mask Shortage in the COVID-19 Pandemic. A Feasibility Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States, 73104
- Oklahoma City VA Health Care System
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
1. All individuals older than 18 years of age, and willing to participate in the study
Exclusion Criteria:
- Individuals with known severe COPD/emphysema, Obesity Hypoventilation or hypercapnic condition
- Individuals with allergy or reactions to latex or masks
- Individuals reporting dyspnea or unable to breathe comfortably in these masks
- Claustrophobic individuals
- Inability to create a proper Seal while inhaling through a closed filter (See Below)
- Individuals who cannot safely apply and remove these masks
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Other: Assembled Mask
Participant will be fitted with a full-face mask that covers the mouth and nose or a Whole face mask that covers the eyes, nose, and mouth depending on participant's preferences.
The Fitted Mask will be attached to a bacterial/viral filter for fit testing.
After completing the Fit test, the mask will be placed on the face for 15 minutes while the participant performs various activities to document the ability to tolerate the respirator.
Participants oxygen and carbon dioxide level will be measured in the beginning and at the end of the 15 minutes.
The individuals will be able to remove the Mask anytime if they experience significant discomfort or claustrophobia.
At the end, the mask will be removed.
|
Assembled masks consisting of 3 parts: A facemask (Respironics Performax Whole Face Mask or Hans Rudolph mask naso-oral mask) linked by a blue elbow ( RP Performax SE ELBOW) to a ventilator filter (Teleflex Bacterial/Viral filter 1605 or Iso-Gard HEPA light Filter 28022)
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Success Percentage
Time Frame: 15 minutes
|
Conduct a quantitative fit test and calculate the percentage of participants who pass the test.
|
15 minutes
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
End-tidal CO2 Variation. Description: mmHg.
Time Frame: at 0 and 15 minutes
|
Change in end-tidal CO2 from 0 to 15 minutes while wearing the Full or the Whole mask
|
at 0 and 15 minutes
|
|
Oxygen Pulse Oximetry Variation. Description: mmHg.
Time Frame: at 0 and 15 minutes.
|
Measure the change in Oxygen Pulse Oximetry from 0 to15 minutes while wearing the Full or the Whole mask
|
at 0 and 15 minutes.
|
|
Mask Visibility. Description: Likert Scale.
Time Frame: 15 minutes
|
Evaluate the visibility (5-point Likert scale from Absent to Complete) while wearing the Full or the Whole mask for 15 minutes
|
15 minutes
|
|
Willingness of usage. Description: Likert Scale.
Time Frame: after 15 minutes
|
When the mask is removed, participants will be asked about willingness to use this mask compared to N-95 masks using a 5-point Likert scale from 'Very unlikely' to 'Very likely'.
|
after 15 minutes
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Houssein Youness, MD, University of Oklahoma HSC - OKC Veterans Affairs Medical Center
Publications and helpful links
General Publications
- van Doremalen N, Bushmaker T, Morris DH, Holbrook MG, Gamble A, Williamson BN, Tamin A, Harcourt JL, Thornburg NJ, Gerber SI, Lloyd-Smith JO, de Wit E, Munster VJ. Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1. N Engl J Med. 2020 Apr 16;382(16):1564-1567. doi: 10.1056/NEJMc2004973. Epub 2020 Mar 17. No abstract available.
- Prevention CfDCa. Strategies for Optimizing the Supply of Facemasks: COVID-19. https://www.cdc.gov/coronavirus/2019-ncov/hcp/ppe-strategy/face-masks.html
- Qian Y, Willeke K, Grinshpun SA, Donnelly J, Coffey CC. Performance of N95 respirators: filtration efficiency for airborne microbial and inert particles. Am Ind Hyg Assoc J. 1998 Feb;59(2):128-32. doi: 10.1080/15428119891010389.
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 11887
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Coronavirus Infection
-
NCT04276688CompletedNovel Coronavirus Infection
-
NCT04281693UnknownNovel Coronavirus Infection Pneumonia
-
NCT05364268CompletedCoronavirus Disease 2019 | SARS-CoV-2 Infection | COVID-19 Pandemic | COVID-19 Virus Infection | Coronavirus Disease-19 | COVID-19 Virus Disease | 2019 Novel Coronavirus Disease | 2019 Novel Coronavirus Infection | 2019-nCoV Disease
-
NCT04335084CompletedCOVID-19 | Coronavirus Infection | COVID | Corona Virus Infection | Coronavirus | Sars-CoV2 | Coronavirus-19 | Coronavirus 19
-
NCT05220579CompletedCoronavirus Infection COVID-19
-
NCT04470583UnknownCOVID-19 | COVID-19 Infection | 2019 Novel Coronavirus Infection
-
NCT07552779RecruitingRespiratory Tract Diseases | COVID-19 | Pneumonia | Lung Diseases | Coronavirus Disease 2019 | Coronavirus Disease 2019 (COVID-19) | COVID-19 Infection | Upper Respiratory Tract Infections | Respiratory Tract Infection | COVID-19 (Coronavirus Disease 2019)
Clinical Trials on Assembled mask
-
NCT05373342Not yet recruitingChildbirth | Surgical Item, Retained
-
NCT07193134RecruitingRecessive Dystrophic Epidermolysis Bullosa | Epidermolysis Bullosa Dystrophica, Recessive | RDEB
-
NCT02811601CompletedUrologic Diseases
-
NCT02805517TerminatedLaparoscopic Donor Nephrectomy
-
NCT06079866CompletedObstructive Sleep Apnea
-
NCT06212180Not yet recruitingCOPD Exacerbation | Acute Respiratory Failure | Hypercapnia | Hypoventilation Obesity Syndrome
-
NCT05150613Completed
-
NCT01575665CompletedHyperventilation | Dysfunctional Breathing | Chronic Idiopathic Hyperventilation | Respiratory Alkalosis